Ekso Bionics (NASDAQ:EKSO – Get Free Report) and Venus Concept (NASDAQ:VERO – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends and risk.
Insider & Institutional Ownership
6.4% of Ekso Bionics shares are held by institutional investors. Comparatively, 87.4% of Venus Concept shares are held by institutional investors. 6.0% of Ekso Bionics shares are held by company insiders. Comparatively, 28.0% of Venus Concept shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Ekso Bionics and Venus Concept, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Ekso Bionics | 1 | 0 | 2 | 0 | 2.33 |
| Venus Concept | 1 | 0 | 0 | 0 | 1.00 |
Risk & Volatility
Ekso Bionics has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500. Comparatively, Venus Concept has a beta of 0.05, suggesting that its stock price is 95% less volatile than the S&P 500.
Valuation and Earnings
This table compares Ekso Bionics and Venus Concept”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Ekso Bionics | $14.65 million | 1.00 | -$11.33 million | ($6.64) | -0.84 |
| Venus Concept | $64.83 million | 0.05 | -$47.00 million | ($50.78) | -0.05 |
Ekso Bionics has higher earnings, but lower revenue than Venus Concept. Ekso Bionics is trading at a lower price-to-earnings ratio than Venus Concept, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Ekso Bionics and Venus Concept’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Ekso Bionics | -75.66% | -86.60% | -41.70% |
| Venus Concept | -68.77% | -871.77% | -61.92% |
Summary
Ekso Bionics beats Venus Concept on 9 of the 14 factors compared between the two stocks.
About Ekso Bionics
Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. The company provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; Ekso Indego Therapy, an adjustable and lower-limb powered exoskeleton; Ekso Indego Personal, a powered lower limb orthosis; Ekso Nomad, a power knee ankle foot orthosis; and Ekso EV, a wearable upper body exoskeleton that elevates and supports a worker's arms to assist with tasks from chest height to overhead. Ekso Bionics Holdings, Inc. was founded in 2005 and is headquartered in San Rafael, California.
About Venus Concept
Venus Concept Inc., a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally. Its product portfolio includes Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; Venus Versa Pro; and Venus Viva and Venus Viva MD, an advanced, portable, and fractional RF system for dermatological procedures requiring ablation and resurfacing of the skin. The company also offers Venus Fiore, a device that delivers non-thermal RF with massage and magnetic field pulses to treat various medical conditions; Venus Bliss and Venus Bliss Max for non-invasive lipolysis of the abdomen, back, thights, and flanks in individuals with a body mass index of 30 or less; Venus Glow, a dermabrasion device used to improve skin appearance; and NeoGraft, an advanced hair restoration technology with an automated FUE and implantation system. In addition, it provides Venus Velocity and Venus Epileve for hair removal, permanent hair reduction, and treatment of pseudofolliculitis barbae; ARTAS iX, a robotic system to assist physicians in identifying and extracting hair follicles units from the scalp during hair transplantation, creating recipient sites, and implanting the harvested hair follicles; and AI.ME an interactive, image-guided, and computer assisted system for fractional skin resurfacing. The company is headquartered in Toronto, Canada.
Receive News & Ratings for Ekso Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics and related companies with MarketBeat.com's FREE daily email newsletter.
